Workflow
抗病毒/抗感染
icon
Search documents
又有上市公司财务造假被严查
Jin Rong Shi Bao· 2025-07-16 01:20
此外,*ST苏吴通过支付无商业实质的贸易业务采购款等形式向关联方提供资金,形成关联方非经营性 占用资金,但未在2020年至2023年年度报告中披露关联方非经营性资金占用,2020年至2023年年度报告 存在重大遗漏。2020年末至2023年末,*ST苏吴关联方非经营性资金占用余额分别为1.27亿元、13.93亿 元、15.43亿元和16.93亿元,占当期披露净资产的6.88%、74.2%、84.6%和96.09%。 中国证监会拟决定对*ST苏吴责令改正,给予警告,并对上市公司及相关责任人罚款总计达3050万元。 与此同时,钱群山作为*ST苏吴实际控制人、董事长、高级管理人员,组织、指使实施案涉事项,行为 恶劣,情节较为严重,拟被采取10年证券市场禁入措施。 又有上市公司或被强制退市。7月13日,江苏吴中医药发展股份有限公司(以下简称"*ST苏吴")披露 公告称,收到中国证监会下发的《行政处罚事先告知书》,公司因连续多年财务造假,拟被处以1000万 元罚款,同时触及上市规则中重大违法强制退市情形,后续将根据最终作出的行政处罚决定,依规实施 退市。 近年来,上市公司财务造假屡禁不止、性质恶劣,严重扰乱资本市场秩序 ...
深夜突发!600200,或重大违法强制退市!
Zhong Guo Ji Jin Bao· 2025-07-13 16:12
Core Viewpoint - *ST Suwu has received an administrative penalty notice from the China Securities Regulatory Commission (CSRC), indicating that the company may face major illegal delisting due to inflated revenue, costs, and profits in its annual reports from 2020 to 2023 [2][5][7]. Summary by Relevant Sections Administrative Penalty Notice - The notice states that *ST Suwu's subsidiaries engaged in non-commercial trade activities with related companies, leading to inflated financial figures [5][7]. - The company is at risk of being delisted under the Shanghai Stock Exchange's rules due to these violations [2][10]. Financial Impact - The inflated revenue figures from 2020 to 2023 were reported as follows: - 2020: 495 million yuan (26.46%) - 2021: 469 million yuan (26.39%) - 2022: 431 million yuan (21.26%) - 2023: 377 million yuan (16.82%) [7]. - The inflated costs were: - 2020: 481 million yuan (37.08%) - 2021: 448 million yuan (35.47%) - 2022: 411 million yuan (28.40%) - 2023: 355 million yuan (20.95%) [7]. - The inflated profit figures were: - 2020: 14.58 million yuan (2.89%) - 2021: 20.27 million yuan (51.65%) - 2022: 19.92 million yuan (26.42%) - 2023: 21.22 million yuan (29.81%) [7]. Company Response and Future Actions - *ST Suwu has issued its first risk warning regarding the potential for major illegal delisting [8]. - If the company receives a formal penalty decision confirming the violations, it will apply for a trading suspension and disclose relevant information [10]. - The Shanghai Stock Exchange will issue a notice regarding the potential termination of *ST Suwu's stock listing within five trading days of the suspension [10]. Recent Financial Performance - For the year 2024, *ST Suwu reported: - Revenue of 1.599 billion yuan, a decrease of 28.64% year-on-year - Net profit attributable to shareholders of 70.48 million yuan, compared to a loss of 71.95 million yuan in 2023 [10][11].
深夜突发!600200,或重大违法强制退市!
中国基金报· 2025-07-13 16:01
【 导读 】*ST苏吴收到《行政处罚事先告知书》, 或 被实施重大违法强制退市 中国基金报记者 闻言 7月13日晚间, *ST苏吴 发布 公告称,公司收到中国证监会下发的《行政处罚事先告知书》,认定公司虚增营业收入、营业成本和利润, 2020年至2023年年报存在虚假记载。 《行政处罚事先告知书》显示,*ST苏吴的上述事项将触及《上海证券交易所股票上市规则》第9.5.2条第一款第(六)项规定的重大违法 强制退市情形, 可能被实施重大违法强制退市。 自7月14日起,*ST苏吴将被叠加实施退市风险警示。截至7月11日收盘,*ST苏吴股价报2.42元/股,总市值为17.23亿元。 2020年至2023年年报存在多项虚假记载 公告显示,7月13日,*ST苏吴收到《行政处罚事先告知书》,监管认定*ST苏吴的子公司江苏吴中进出口有限公司、中吴贸易发展(杭 州)有限公司、江苏吴中海利国际贸易有限公司通过与浙江优诺德贸易有限公司等多家关联公司开展无商业实质的贸易业务,虚增营业收 入、营业成本和利润。 此外,《行政处罚事先告知书》显示,*ST苏吴未如实披露实际控制人,2018年至2023年年报存在虚假记载;未按规定披露关联方非 ...
突发!600200,董事长被证监会立案!
证券时报· 2025-05-14 14:44
以下文章来源于e公司 ,作者证券时报 刘灿邦 e公司 . e公司,证券时报旗下专注上市公司新媒体产品,立志打造A股上市公司资讯第一平台。提供7x24小时上市公司标准化快讯,针对可能影响上市公司股价 的主题概念、行业事件及时采访二次解读,从投资者需求出发,直播上市公司有价值的活动、会议。 董事长被证监会立案调查,公司2024年年报因资金占用事项被出具非标意见。 5月14日晚间,*ST苏吴(600200)公告,公司收到董事长钱群山通知,其于近日收到中国证监会出具的《立案告知书》(编号:证监立案字0392025008 *ST苏吴表示,本次立案仅针对钱群山个人,不会对公司日常经营活动产生重大影响。立案调查期间,钱群山将积极配合中国证监会的调查工作。 记者注意到,今年2月26日,*ST苏吴收到中国证监会《立案告知书》(证监立案字0392025006号),因公司涉嫌信息披露违法违规,根据《中华人民共和国 证券法》等法律法规,中国证监会决定对公司立案。彼时,*ST苏吴表示,若后续经中国证监会行政处罚认定的事实,触及上交所规定的重大违法强制退市情 形,公司股票将被实施重大违法强制退市。 5月14日晚间披露的另一则公告显示,截 ...
突发!600200,董事长被证监会立案
Core Viewpoint - The chairman of *ST Suwu is under investigation by the China Securities Regulatory Commission (CSRC) for suspected violations of information disclosure laws, which may impact the company's financial reporting and operations in the future [1][2]. Group 1: Investigation and Regulatory Actions - The CSRC has issued a notice of investigation against chairman Qian Qunshan, which is solely directed at him and is not expected to significantly affect the company's daily operations [1]. - The company has received a non-standard opinion on its 2024 annual report due to issues related to the occupation of funds, with a significant amount of 769 million yuan occupied by related parties [4]. - The company will provide weekly updates on the investigation's progress during the ongoing inquiry [2]. Group 2: Financial Performance - For the year 2024, *ST Suwu reported a revenue of 1.599 billion yuan, representing a year-on-year decrease of 28.64%, and a net profit attributable to shareholders of 70.48 million yuan [4]. - The company has received an audit report from Zhongxing Caiguanghua Accounting Firm that expresses an inability to provide an opinion on the financial statements due to the aforementioned issues [4]. Group 3: Business Operations and Strategy - *ST Suwu operates in the pharmaceutical sector through its wholly-owned subsidiary, Jiangsu Wuzhong Pharmaceutical Group, focusing on drug research, production, and sales, with key products in various therapeutic areas [2]. - The company aims to develop a dual-driven strategy focusing on both industrial development and capital operations, with plans to enhance its pharmaceutical core while nurturing the medical beauty biotechnology sector as a complementary industry [4]. Group 4: Legal and Financial Challenges - The company’s subsidiary, Jiangsu Wuzhong Import and Export Co., faced legal issues related to export tax fraud, with a court hearing scheduled for April 22, 2025 [5]. - Due to overdue loans, some of the company's bank accounts have been frozen, which may further impact its financing capabilities and business operations [5].